Fannin Partners, a Houston-based life science firm developing early-stage therapeutic and medical device technologies, has been awarded two additional grants to further develop its novel phosphodiesterase 4B (PDE4B) inhibitors for neurological conditions.

Therapeutic Will Be Tested for Potency, Specificity, and Side Effects for the Treatment of Opioid-Use Disorder Under This Proposal